Skip to main content
. Author manuscript; available in PMC: 2018 Aug 24.
Published in final edited form as: Lancet Infect Dis. 2014 Jul 22;14(9):820–829. doi: 10.1016/S1473-3099(14)70847-3

Figure 2.

Figure 2

HIV-1 Incidence and TFV-DP in DBS. For those visits on PrEP, the incidence of HIV is estimated by exponential regression by TFV-DP in DBS. The incidence for the prior placebo group is depicted as a constant for reference. The dotted lines represent the estimate bounded by one standard error. Dosing for each interval is estimated by pharmacokinetic modeling. The hazard ratios were adjusted for study site, age, ncRAI at entry and syphilis. TFV-DP measurements were not available for 5% of visits in the cohort.